---
title: "CANBRIDGE-B's self-developed CAN 103 has been included in China's first edition of the \"Commercial Insurance Innovative Drug Catalog.\""
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/268933358.md"
description: "CANBRIDGE-B's innovative drug CAN 103 has been included in the first version of China's \"Commercial Insurance Innovative Drug Catalog,\" which will be implemented on January 1, 2026. CAN 103 is China's first domestically developed enzyme replacement therapy for patients with Gaucher disease and has already been applied clinically. This move is seen as a milestone for the company, ensuring that patients receive safe and effective treatment"
datetime: "2025-12-08T10:17:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268933358.md)
  - [en](https://longbridge.com/en/news/268933358.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268933358.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/268933358.md) | [English](https://longbridge.com/en/news/268933358.md)


# CANBRIDGE-B's self-developed CAN 103 has been included in China's first edition of the "Commercial Insurance Innovative Drug Catalog."

According to the Zhitong Finance APP, CANBRIDGE-B (01228) announced that the group's domestically developed enzyme replacement therapy, CAN 103, has successfully been included in the first version of China's "Commercial Insurance Innovative Drug Directory," which will officially take effect on January 1, 2026.

CAN 103 was approved for market launch on May 13, 2025, and is China's first domestically developed enzyme replacement therapy for long-term use in adolescents aged 12 and older and adults with Type I and Type III Gaucher disease. It is also the first innovative biological drug in China to pass the segmented production inspection for biological products. On July 2, 2025, CAN 103 was prescribed for the first time at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, marking the official entry of the drug into clinical application, which will greatly enhance the accessibility of medication for domestic patients in the future.

The company believes that the inclusion of CAN 103 in this directory is a milestone achievement for the group, as this move will ensure that Gaucher disease patients have access to safe and effective domestically produced enzyme replacement therapy, receiving broader and more comprehensive treatment guarantees

### 相關股票

- [CANBRIDGE-B (01228.HK)](https://longbridge.com/zh-HK/quote/01228.HK.md)

## 相關資訊與研究

- [ZAWYA: “Tamkeen by BelArabi”: Two female startups, one game-changing opportunity, applications open](https://longbridge.com/zh-HK/news/281489198.md)
- [Uber CEO Dara Khosrowshahi Hopes To Incorporate Tesla Robotaxis On Its Platform: 'It's A Great Car…'](https://longbridge.com/zh-HK/news/281491777.md)
- [11:01 ETPureHealth Research Liver Health Supplements Target Fatty Liver for Improved Daily Energy](https://longbridge.com/zh-HK/news/281689012.md)
- [BrYet US, Inc. to Present ML-016 Preclinical Efficacy Data at AACR 2026](https://longbridge.com/zh-HK/news/281647557.md)
- [BYD launches 2026 Seal 06 GT and wagon models equipped with ultra-fast charging tech](https://longbridge.com/zh-HK/news/281493817.md)